SCHEMBL623746

SCHEMBL623746

CCOc1cccc(C(=O)N2CCN(c3cc(OCC(C)C)ncn3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.43
KCNK9 Q9NPC2 1/20 0.43
ACACB O00763 1/20 0.41
IRAK4 Q9NWZ3 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
CCKAR P32238 3/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
MAPK1 P28482 1/20 0.37
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
LRRK2 Q5S007 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623267 0.91 KCNK3 (0.43) KCNK3KCNK9IRAK4HRH3CCKAR
SCHEMBL624371 0.89 KCNK3 (0.44) KCNK3KCNK9ACACBIRAK4HRH3
SCHEMBL622299 0.88 ELOVL1 (0.40) HRH3TSHRMEN1KMT2A
SCHEMBL624496 0.83 TSHR (0.53) CCKARSMN1; SMN2MAPK1MAPTTSHR
SCHEMBL622785 0.83 GAA (0.41) CCKARTSHRRAB9AKMT2A
SCHEMBL623165 0.82 CCKAR (0.44) CCKARTSHRMEN1KMT2A
SCHEMBL623189 0.82 PTK2 (0.51) TSHRMEN1KMT2A
SCHEMBL623692 0.80 HRH4 (0.47) SMN1; SMN2USP2MAPK1ITGB2ICAM1
SCHEMBL623239 0.79 ALDH1A1 (0.52) SMN1; SMN2MAPTL3MBTL1LMNATSHR
SCHEMBL623777 0.79 P2RY12 (0.46) MAPK1LMNATSHRRAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G KCNK3 102/4885KCNK9 163/4885ACACB 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.